While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Type 1 diabetes (T1D) is an autoimmune condition where the body cannot produce insulin properly, and this can affect the life ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Ozempic is sold in injection pens containing 0.25 and ... is sold by Sanofi under the brand name Soliqua. Soliqua contains a combination of lixisenatide and insulin. It is registered for the treatment ...

Eli Lilly’s big-selling insulin ... in vial form or as a disposable pen. Sanofi fights back This represents Sanofi's first foray into the biosimilar diabetes market, and has been persuaded ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The insulin glargine and lixisenatide combination is only available as the brand-name drug Soliqua ... There are five pens per box of Soliqua 100/33. For treating type 2 diabetes, your doctor ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Q1 2025 Earnings Call Transcript February 6, 2025 Embecta Corp. beats earnings expectations. Reported EPS is $0.65, ...

At the same time, we are continuing to identify opportunities within our core portfolio that bolster our leadership position in insulin ... as the pen needles used for diabetes.

Mounjaro is a brand-name medication ... blood sugar levels and improving the body’s response to insulin helps manage type 2 diabetes better, which may also aid in weight loss.